04.12.23
Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has appointed Thomas aus dem Siepen as Global Head Digital Manufacturing and Automation. As an experienced leader, he is a member of Rentschler Biopharma's Global Leadership Team and is responsible for the alignment of digitalization and automation, from R&D to production.
Before joining the company, Thomas aus dem Siepen worked for more than 16 years in various management positions with increasing responsibility at Roche Diagnostics. There, he headed the “MSAT Process Automation” department, which included ownership, control, operation and further development of production-related IT and automation systems for pharmaceutical and clinical production as well as laboratory IT.
Most recently, he established an end-to-end support organization strongly aligned with the Drug Substance core business, the “Manufacturing Value Stream”, which oversaw the entire range of process-relevant configuration of manufacturing processes across all levels of automation and their data use. In addition to the coordination of a large team, his tasks included the creation of strategic roadmaps and the establishment of a global network between the Drug Substance sites for the cooperation and strategic alignment of automation concepts and their standardization.
Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, said: “I am pleased to welcome Thomas aus dem Siepen to Rentschler Biopharma. He brings strong experience in digital manufacturing. This sub-area of Industry 4.0 aims to digitize and intelligently network production workflows to advance the automation of processes. With his in-depth experience, Thomas aus dem Siepen will make an important contribution to digital excellence at Rentschler Biopharma by connecting the employees of the departments even better with each other. Highly efficient internal planning processes are crucial so that we can focus on our main purpose: to sustainably improve the lives of patients.”
Before joining the company, Thomas aus dem Siepen worked for more than 16 years in various management positions with increasing responsibility at Roche Diagnostics. There, he headed the “MSAT Process Automation” department, which included ownership, control, operation and further development of production-related IT and automation systems for pharmaceutical and clinical production as well as laboratory IT.
Most recently, he established an end-to-end support organization strongly aligned with the Drug Substance core business, the “Manufacturing Value Stream”, which oversaw the entire range of process-relevant configuration of manufacturing processes across all levels of automation and their data use. In addition to the coordination of a large team, his tasks included the creation of strategic roadmaps and the establishment of a global network between the Drug Substance sites for the cooperation and strategic alignment of automation concepts and their standardization.
Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, said: “I am pleased to welcome Thomas aus dem Siepen to Rentschler Biopharma. He brings strong experience in digital manufacturing. This sub-area of Industry 4.0 aims to digitize and intelligently network production workflows to advance the automation of processes. With his in-depth experience, Thomas aus dem Siepen will make an important contribution to digital excellence at Rentschler Biopharma by connecting the employees of the departments even better with each other. Highly efficient internal planning processes are crucial so that we can focus on our main purpose: to sustainably improve the lives of patients.”
